Mykronor (Noradrenaline Tartrate)

• Mykronor is employed as a vasopressor in critical care settings to manage life‑threatening low‑blood‑pressure states.
• Acute hypotension: rapidly increases systemic vascular resistance, helping to restore adequate arterial pressure and organ perfusion in patients with sudden drops in blood pressure.
• Septic shock: counteracts profound vasodilation, improving mean arterial pressure and supporting organ function during severe infection‑related circulatory failure.
• Cardiac arrest: provides essential support to coronary and cerebral perfusion during resuscitation, enhancing the chance of return of spontaneous circulation.

• Norepinephrine acts as an alpha‑adrenergic receptor agonist, primarily stimulating α1 receptors on vascular smooth muscle. This induces vasoconstriction, raising systemic vascular resistance and arterial pressure. At higher concentrations, it also stimulates β1 receptors in the heart, modestly increasing cardiac output. The combined effect restores hemodynamic stability in patients with severe hypotension.

Adverse reactions may occur with norepinephrine administration.

Common Side Effects

• Headache: mild to moderate discomfort often related to rapid blood pressure changes.
• Tachycardia: increased heart rate due to β1‑adrenergic stimulation.
• Peripheral ischemia: reduced blood flow to extremities causing coldness or discoloration.
• Nausea: gastrointestinal upset experienced by some patients.

Serious or Rare Side Effects

• Severe hypertension: excessive rise in blood pressure that can lead to vascular injury.
• Myocardial ischemia: reduced coronary blood flow causing chest pain or infarction.
• Tissue necrosis: local injury at infusion sites if extravasation occurs.
• Anaphylaxis: rare allergic reaction requiring immediate intervention.

Use of Mykronor requires careful clinical monitoring and adherence to safety guidelines.

• Monitor blood pressure continuously: adjust infusion rate to maintain target pressures.
• Assess volume status before initiation: ensure adequate intravascular volume to avoid worsening hypoperfusion.
• Use with caution in patients with cardiac disease: heightened risk of arrhythmias.
• Avoid in patients with known hypersensitivity to norepinephrine or its excipients.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Norepinephrine may interact with other cardiovascular agents, altering its efficacy or safety.

Major Interactions (Avoid)

• MAO inhibitors: can potentiate hypertensive crises.
• Beta‑blockers: may blunt desired heart‑rate response.
• Vasodilators (e.g., nitroglycerin): can counteract vasopressor effect.

Moderate Interactions (Monitor Closely)

• ACE inhibitors: may enhance hypotensive episodes if volume is insufficient.
• Diuretics: can exacerbate volume depletion, requiring careful fluid management.